The association between Heart failure and Systemic inflammatory response index: A cross‐sectional study

Background: The Systemic Inflammatory Response Index (SIRI) is a novel inflammatory composite measure widely utilized for evaluating the prognosis of patients with cardiovascular and cerebrovascular disorders and cancer. It has been proven that people with heart failure (HF) have a chronic inflammatory response in their hearts. The aim of this study is to evaluate the potential connection between SIRI with HF. Methods: The cross-sectional investigation used National Health and Nutrition Examination Survey (NHANES) database information from 2009 to 2018. SIRI is computed using the monocyte, neutrophil, and lymphocyte counts. The Monetary Choice Questionnaire (MCQ) results define HF. The linear association between SIRI and HF was analyzed using a weighted linear regression model with multiple variables. The nonlinear link was defined using smoothing curve fittings and threshold effect analysis. Results: 26,361 individuals were included in our analysis; HF was diagnosed in 3.26% of participants, and this proportion increased with higher SIRI levels (Quartile 1, 1.76%; Quartile 2, 1.87%; Quartile 3, 2.98%; Quartile 4, 6.43%; p for trend <0.001). Multiple logistic regression analysis demonstrated a relationship between higher SIRI levels and an elevated chance of HF (OR = 1.15;95% CI, 1.05-1.27, p=0.0029). In addition, a nonlinear relationship existed between SIRI and HF. A two-segment linear regression model showed an inverse S-shaped connection between SIRI with HF by an inflection point of 2.66 (1,000 cells/μl). In males the SIRI-HF association was inverted U-shaped, with an inflection point at 2.8 (1,000 cells/μl) after stratification; among females, there was no statistically significant inflection point. Conclusions: Our results imply the existence of a positive correlation between HF. To corroborate the association between SIRI and HF, that was required to perform prospective investigations on a huge scale and clinical experiments.